ERNA (Ernexa Therapeutics) Other Current Receivables: $0.10 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ERNA Ernexa Therapeutics Inc ERNA
30 GF Score
Price $6.46
! 4 Warning Signs
View Full Analysis

What is Ernexa Therapeutics Other Current Receivables?

Ernexa Therapeutics ERNA -9.83% 30 Other Current Receivables is $0.10 Mil as of Mar. 2026. GuruFocus rates ERNA with a GF Score™ of 30/100. The stock has 4 warning signs investors should review.

Ernexa Therapeutics's Other Current Receivables for the quarter that ended in Mar. 2026 was $0.10 Mil.

Ernexa Therapeutics's quarterly Other Current Receivables increased from Sep. 2025 ($0.15 Mil) to Dec. 2025 ($0.85 Mil) but then stayed the same from Dec. 2025 ($0.85 Mil) to Mar. 2026 ($0.10 Mil).

Ernexa Therapeutics's annual Other Current Receivables increased from Dec. 2023 ($0.43 Mil) to Dec. 2024 ($0.44 Mil) and increased from Dec. 2024 ($0.44 Mil) to Dec. 2025 ($0.85 Mil).

Ernexa Therapeutics Other Current Receivables Related Terms

Ernexa Therapeutics Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Ernexa Therapeutics's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ernexa Therapeutics Other Current Receivables Chart

Ernexa Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Receivables
Get a 7-Day Free Trial 0.68 0.95 0.43 0.44 0.85

Ernexa Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.16 0.15 0.15 0.85 0.10
ERNA
30GF Score
Ernexa Therapeutics Inc ERNA
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ernexa Therapeutics Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of $0.10 Mil mean?
Ernexa Therapeutics (ERNA) has a Other Current Receivables of $0.10 Mil as of Mar. 2026. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Ernexa Therapeutics and its competitors.
Is Ernexa Therapeutics' Other Current Receivables too high?
Ernexa Therapeutics' current Other Current Receivables is $0.10 Mil. Overall, Ernexa Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Ernexa Therapeutics' Other Current Receivables compare to PMCB and SYBX?
Ernexa Therapeutics' Other Current Receivables of $0.10 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Biotechnology company?
A good Other Current Receivables depends on the Biotechnology industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Ernexa Therapeutics and its competitors. Ernexa Therapeutics's current Other Current Receivables is $0.10 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ernexa Therapeutics stock overvalued right now?
Ernexa Therapeutics (ERNA) has a current Other Current Receivables of $0.10 Mil. The current Other Current Receivables is $0.10 Mil. Ernexa Therapeutics' overall GF Score™ is 30/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Ernexa Therapeutics (ERNA), the current Other Current Receivables is $0.10 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ernexa Therapeutics Business Description

Address 1035 Cambridge Street, Suite 18A, Cambridge, MA, USA, 02141
Ernexa Therapeutics Inc is a preclinical-stage synthetic allogeneic iMSC therapy company developing medicines to treat various forms of cancer and other diseases with high unmet medical needs. Its main product candidate, ERNA-101, capitalizes on the intrinsic tumor-homing ability of MSCs (mesenchymal stem cells) to slip through the tumor's defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment. The firm's initial focus is to develop ERNA-101 in platinum-resistant ovarian cancer. Through another product candidate, ERNA-201, it is investigating anti-inflammatory cytokine (IL-10) secreting iMSCs in autoimmune disorders like rheumatoid arthritis. The company operates in a single reportable segment, the research and development of cellular therapies.
30GF Score

Get the complete analysis for ERNA

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.46
Price